published meta-analysis   sensitivity analysis   studies

cilgavimab and tixagevimab (Evusheld) in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] 0.70[0.50; 0.97]ACTIV-3/TICO (tixa), 202210%1,417NAnot evaluable deaths (time to event analysis only)detailed resultsACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] 0.70[0.50; 0.97]ACTIV-3/TICO (tixa), 202210%1,417NAnot evaluable clinical improvementdetailed resultsACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20] 1.08[0.97; 1.20]ACTIV-3/TICO (tixa), 202210%1,417NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:15 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 888 - roots T: 290